Related Experiment Videos
[Invasive pulmonary aspergillesis].
Terapevticheskii Arkhiv
|August 25, 2005
Summary
Invasive pulmonary aspergillosis (IPA) therapy yielded a 56% lethality rate with amphotericin B. Early diagnosis and voriconazole administration may reduce mortality in IPA patients.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pulmonology
Background:
- Invasive pulmonary aspergillosis (IPA) is a serious fungal infection, particularly in immunocompromised patients.
- This study reviews IPA cases treated between 2000 and 2005 at a single medical center.
Purpose of the Study:
- To evaluate the therapeutic outcomes of invasive pulmonary aspergillosis (IPA).
- To assess the effectiveness of different antifungal agents and treatment strategies.
Main Methods:
- Diagnosis of IPA followed international criteria.
- Data collected included patient demographics, underlying conditions, diagnostic methods, and treatment regimens.
- Treatment outcomes, including cure rates and lethality, were analyzed.
Main Results:
- IPA was diagnosed in 50 cases, with acute leukemia being the most common underlying condition (54%).
- Mortality due to IPA was 56%, with 90-day survival at 47%.
- Amphotericin B showed 29% effectiveness, while voriconazole and caspofungin had higher response rates in limited cases.
Conclusions:
- High lethality (56%) was observed with amphotericin B as the primary therapy for IPA.
- Early diagnosis and prompt initiation of voriconazole are crucial for reducing IPA-related mortality.
- Further multicenter studies are needed to establish optimal combined antifungal therapy protocols.